

MBC 101: Understanding the Basics

Stage IV Stampede & Summit 2025










WHAT YOU NEED TO KNOW

- Biology 101: become an expert in 7 easy minutes
- What is metastatic breast cancer (MBC) and how it differs from early stage disease?
- When and how does breast cancer spreads from the breast to different sites?
- The importance of subtype and other biomarkers to treatments
- How treatments are discovered and move to the clinic, including the importance of federal funding
- How common MBC is, other statistics, and challenges to knowledge in this area due to how the US collects data including SEER




Biology 101: cells as building materials





Biology 101: genes as building instructions







Biology 101: mutations

as instruction errors

NORMAL GENE




MUTATED GENE





What is breast cancer?


- Cancer: cells divide out of control, don't die, and invade other tissues
- Breast cancer:
 - Cancer that starts in the breast







What is breast cancer?

- Cancer: cells divide out of control, don't die, and invade other tissues
- Breast cancer:
 - Cancer that starts in the breast
 - Types:
 - Invasive ductal carcinoma: majority
 - Invasive lobular carcinoma: ~15%
 - Other, rarer types
- Early stage breast cancer
 - Stages 0-3
 - Has **not** spread to a distant site
 - Specific stage determined by invasiveness, tumor size, and local lymph node involvement










What is metastatic


breast cancer?

- Cancer: cells divide out of control, don't die, and invade other tissues
- Metastatic cancers: spread to sites distant from the original tumor & grow
- Metastatic (stage 4) breast cancer:
 - Cancer cells spread from primary breast tumor & grow
 - Can happen very early before a tumor is detectable.
 - De novo MBC: no early stage diagnosis
 - Recurrent MBC: early stage diagnosis followed by MBC diagnosis






- Differs by **subtype**
 - Different subtypes respond to treatments differently,
 behave differently, and can have different prognoses
 - Three protein receptors determine subtype
 - Estrogen receptor
 - Progesterone receptor
 - HER2





• Differs by **subtype**


- Different subtypes respond to treatments differently,
 behave differently, and can have different prognoses
- Three protein receptors determine subtype
 - Estrogen receptor
 - Progesterone receptor
 - HER2
- Leads to
 - Hormone receptor positive (ER+ and/or PR+)
 - HER2 positive (HER2+)
 - Triple positive (ER+ PR+ HER2+)
 - Triple negative (ER- PR- HER2-)






• Differs by subtype

- Different subtypes respond to treatments differently, behave differently, and can have different prognoses
- Three protein receptors determine subtype
 - Estrogen receptor
 - Progesterone receptor
 - HER2
- Leads to
 - Hormone receptor positive (ER+ and/or PR+)
 - HER2 positive (HER2+)
 - Triple positive (ER+ PR+ HER2+)
 - Triple negative (ER- PR- HER2-)
- Some nuance
 - HER2 low & ultralow
 - ER low positive
- Can change over time and by tumor location
- How do I know my subtype? Ask oncologist, see pathology report(s)




- Differs by mutations
 - Mutations: changes in the DNA sequence that can lead to changes in proteins & cell behavior
 - Inherited mutations (genetic testing)
 - Inherited from biological parent(s)
 - In all your cells
 - Can be passed on to biological children
 - Examples: BRCA 1 & 2 mutations, CHEK2 mutations etc.
 - Acquired mutations (genomic or biomarker testing)
 - Cancer cells pick these up over time
 - Can't be inherited or passed on to children
 - Examples: ESR1 mutations, PIK3CA mutations





Treatments: from the lab to the clinic

- Basic research science
 - Provides the foundation, "whys" and "hows"
- Translational research
 - Pivot point between the bench and the bedside,
 "whats" can be done
 - Preclinical research
 - In cells
 - In mice and other animals
 - In computers
- Clinical trials in humans
 - Phase 1: safety & dosing
 - Phase 2: side effects & effectiveness
 - Phase 3: side effects & comparison to currently approved therapy
- FDA approval






Treatments: from the lab to the clinic

• • •

- The role of basic research science
- Translational research
 - Preclinical research
 - In cells
 - In mice and other animals
 - In computers
- Clinical trials in humans
 - Phase 1: safety & dosing
 - Phase 2: side effects & effectiveness
 - Phase 3: side effects & comparison to currently approved therapy
- FDA approval

Drug Discovery and Development Timeline






Some statistics — these are all for reference

- Breast Cancer is the most common cancer among women in the world and the second leading cause of death from cancer in the United States. (Giaquinto et al., 2022)
- In the US in 2024, approximately 42,250 women and 530 men will die of breast cancer. This is equivalent to ~117 people per day. (ACS 2024, Giaquinto et al., 2024)
- In the US there are 150,000-160,000 women living with MBC. (Gallicchio et al., 2022; Mariotto et al., 2017; Giaquinto et al., 2022)
- Only about 30% of MBC patients in the US live longer than 5 years. (ACS 2024, Mariotto et al. 2017)
- The median survival of people diagnosed with MBC in 2019 was estimated at 3.2 years. (Caswell-Jin et al., 2021)
- An estimated 1 in 4 early stage breast cancer will become metastatic. However, this varies greatly from about 10-40% due to large differences in risk of distant recurrence by stage at diagnosis and the biology of the disease itself. (Early Breast Cancer trials Collaborative Group, 2024)
- Breast cancer can recur as MBC from several months to 25+ years after early-stage treatment. (After Breast Cancer Diagnosis, 2020)



Distribution of Breast Cancer Diagnoses


De Novo Metastatic Breast Cancer (6%)



Of all **breast cancer diagnoses**, 6% are initially diagnosed with stage 4, or de novo, disease.

Of all cases of metastatic breast cancer, 69% are recurrent from a prior early stage diagnosis and 31% are de novo, or initially diagnosed as metastatic.

Distribution of Metastatic Breast Cancer Cases





How common is breast cancer? MBC?

- Breast Cancer is the
 - Most common cancer among women in the world
 - Most common cancer among women & the second highest cause of death from cancer in the United States (after lung cancer).
- In the United States there are
 - Over 4 million people who are currently in treatment or have completed treatment for breast cancer
 - OApproximately 150,000-160,000 women living with MBC.

emales
ses
268,600
111,710
67,100
61,880
39,260
15
66,020
41,760
23,380
21,950
13,980






Breast cancer deaths & MBC survival statistics

- In the US in 2024, approximately 42,250 women and 530 men will die of breast cancer. This is equivalent to ~117 people per day.
- Only about 30% of MBC patients in the US live longer than 5 years.
- The median survival of people diagnosed with MBC in 2019 was estimated at 3.2 years.

5-year breast cancer survival rate for women by stage at diagnosis






SEERing is believing

- What is SEER?
- What facts and statistics can we get from SEER and which require other methods?
 - Of all breast cancer diagnoses, 6% are initially diagnosed with Stage 4 or de novo metastatic disease.
 - In the US in 2024, approximately 42,250 women and 530 men will die of breast cancer. This is equivalent to ~117 people per day.
- What information can we not get directly from SEER? And why not?
- SEER needs modernization, which requires investment







Show me the money

- Just 13% of breast cancer research dollars go toward MBC research.
- While funding for MBC is increasing, we have a long way to go and is still greatly UNDER FUNDED.
- Calculating breast cancer research dollars going to MBC can be done in different ways and is complex! And is why you may see various numbers.
 - O What is included?
 - Research on already metastatic?
 - Research on dormant cells?
 - Research on preventing metastasis?





Knowledge is power

 You know more about MBC than the people you are meeting on Capitol Hill – you are an expert in the lived experience of cancer

Present the facts, which we hope we've given you

Questions??



And thank you to our sponsors...



